Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).

被引：3
|
作者：
Dougherty, Brian
Ledermann, Jonathan A.
Lai, Zhongwu
Robertson, Jane D.
Ho, Tony
Hodgson, Darren R.
O'Connor, Mark J.
Fielding, Anitra
Hawryluk, Matthew J.
Brennan, Tim
Yelensky, Roman
Sun, James
Barrett, J. Carl
机构：
[1] AstraZeneca, Waltham, MA USA
[2] UCL, Inst Canc, London, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] AstraZeneca, Wilmington, DE USA
[5] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5536
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer
    Tomoko Yoshihama
    Yuka Kuroda
    Tatsuyuki Chiyoda
    Mio Takahashi
    Takuma Yoshimura
    Keiko Saotome
    Yoshiko Nanki
    Kensuke Sakai
    Yusuke Kobayashi
    Wataru Yamagami
    Daisuke Aoki
    International Journal of Clinical Oncology, 2022, 27 : 1644 - 1650
  • [42] Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
    Liu, Jihong
    Yin, Rutie
    Wu, Lingying
    Zhu, Jianqing
    Lou, Ge
    Wu, Xiaohua
    Zhou, Qi
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Wang, Jing
    Chen, Youguo
    Cheng, Ying
    Wang, Yueling
    Lu, Weiguo
    Li, Wei
    Ma, Xin
    Hsu, Kate
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 714 - 722
  • [43] Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer
    Yoshihama, Tomoko
    Kuroda, Yuka
    Chiyoda, Tatsuyuki
    Takahashi, Mio
    Yoshimura, Takuma
    Saotome, Keiko
    Nanki, Yoshiko
    Sakai, Kensuke
    Kobayashi, Yusuke
    Yamagami, Wataru
    Aoki, Daisuke
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (10) : 1644 - 1650
  • [44] Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses
    Oza, A. M.
    Cibula, D.
    Oaknin Benzaquen, A.
    Poole, C. J.
    Mathijssen, R. H. J.
    Sonke, G. S.
    Mackay, H.
    Lowe, E. S.
    Read, J.
    Friedlander, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S712 - S713
  • [45] Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
    Li, Huayi
    Peng, Zikun
    Zhu, Jianqing
    Zhao, Weidong
    Huang, Yi
    An, Ruifang
    Zheng, Hong
    Qu, Pengpeng
    Wang, Li
    Zhou, Qi
    Wang, Danbo
    Lou, Ge
    Wang, Jing
    Wang, Ke
    Kong, Beihua
    Xie, Xing
    Yin, Rutie
    Low, John
    Rozita, Abdul Malik
    Sen, Lim Chun
    Meng, Yong Chee
    Kiong, Kho Swee
    Liu, Jihong
    Liang, Zhiqing
    Lv, Weiguo
    Zhu, Yaping
    Hu, Weiguo
    Sun, Wei
    Su, Jingya
    Wang, Qiqi
    Zang, Rongyu
    Ma, Ding
    Gao, Qinglei
    BMC MEDICINE, 2024, 22 (01):
  • [46] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy
    Matulonis, U. A.
    Harter, P.
    Gourley, C.
    Friedlander, M.
    Vergote, I. B.
    Rustin, G. J. S.
    Fielding, A.
    Spencer, S.
    Parry, D.
    Ledermann, J. A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 8 - 8
  • [47] First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)
    Rouge, T. De La Motte
    Pautier, P.
    Alexandre, J.
    Ray-Coquard, I.
    Cottu, P.
    Rodrigues, M.
    Follana, P.
    Floquet, A.
    Lortholary, A.
    Heudel, P. E.
    Combe, P.
    Joly, F.
    Suau, D.
    Maribas, D.
    Licour, M.
    De La Porte, I.
    Varoqueaux, N.
    Pujade-Lauraine, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S548 - S549
  • [48] Phase II study of olaparib plus durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    Kaufman, B.
    Banerjee, S.
    Lortholary, A.
    Hong, S. H.
    Park, Y. H.
    Zimmermann, S.
    Roxburgh, P.
    Ferguson, M.
    Alvarez, R. H.
    Domchek, S.
    Gresty, C.
    Angell, H. K.
    Ros, V. Rocher
    Meyer, K.
    Lanasa, M.
    Herbolsheimer, P.
    de Jonge, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial
    Jiang, Rong
    Feng, Yanling
    Chen, Yulian
    Cheng, Xi
    Shi, Tingyan
    Gao, Wen
    Jia, Huixun
    Jiang, Shiyang
    Guo, Yi
    Huang, Xiao
    Tu, Dongsheng
    Zhang, Yuqin
    Yang, Huijuan
    Zhang, Ping
    Liu, Jihong
    Zhu, Jianqing
    Zang, Rongyu
    NATURE MEDICINE, 2024, 30 (08) : 2181 - 2188
  • [50] Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)
    Penson, R.
    Kaminsky-Forrett, M-C.
    Ledermann, J.
    Brown, C.
    Plante, M.
    Korach, J.
    Huzarski, T.
    Lista, A. Gomez de Liano
    Pisano, C.
    Friedlander, M.
    Colombo, N.
    Gropp-Meier, M.
    Nakai, H.
    Sonke, G. S.
    Kim, J-W.
    Vergote, I.
    Allen, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28
12345